Biosimilars in Europe

Biosimilars in Europe

This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:	Manufacturing industries Medicine and Nursing adalimumab approval award criteria barriers Belgium biological biologics biosimilar biosimilar market biosimilar sustainability biosimilar/supply and distribution biosimilarity assessment biosimilars budget impact analysis clinical clinical governance communication competition competitive market cost containment cost simulation Delphi technique drug costs education etanercept Europe European public assessment reports (EPARs) Germany healthcare costs HER2-positive breast cancer incentives infliximab information interchangeability intravenous market dynamics n/a off-patent patient pharmaceutical spending policies potentially critical quality attributes (pCQAs) pricing procurement quality attributes (QAs) queries reference biological regulatory regulatory science reimbursement review savings Spain subcutaneous sustainability switching tender TNFα inhibitors trastuzumab uptake utilization
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Internet

Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication

Cannot write session to /tmp/vufind_sessions/sess_h58ou26tdp7to5p78gdvfsq11k